Quanterix has realized approximately $85 million of cost savings following its integration efforts, but the life sciences company reduced its 2026 revenue outlook and pushed its expected cash flow breakeven into 2027 amid commercial execution challenges and broader market pressures.
The company said the $85 million of cost savings have been realized following the completion of its planned cost integration and enterprise resource planning work. Quanterix is now focused on improving commercial execution, accelerating revenue growth and strengthening its position in diagnostics.
Quanterix now expects full-year 2026 revenue of $142 million to $148 million, down substantially from its previous outlook of $169 million to $173 million. Adjusted gross margin is expected to range between 48% and 50%, compared with the previous 49% to 53% outlook.
The company also moved its expected cash flow breakeven point to 2027 after previously targeting the second half of 2026. Quanterix nevertheless expects to exit 2026 with approximately $80 million of cash and no debt.
Q2 reported revenue increased 34% year-over-year to $32.9 million from $24.5 million, reflecting the addition of Akoya Biosciences. On a pro forma basis that includes Akoya in the prior-year comparison, however, revenue declined approximately 23% from $42.7 million. Quanterix ended the quarter with a $97 million cash balance.
The underlying revenue environment remained challenging across several parts of the business. Quanterix cited weak commercial execution and continued macroeconomic pressure in the Americas, lower consumables pull-through in EMEA, weakness in U.S. academic and government research funding, and year-over-year pressure in Pharma-CRO. Accelerator revenue also declined, although bookings increased significantly sequentially.
Despite those pressures, the company’s adjusted cost structure improved. Adjusted operating expenses were approximately $31.8 million compared with $31.1 million a year earlier, while adjusted operating loss narrowed to $16 million from $20.9 million. Adjusted EBITDA loss improved to approximately $10 million from $13.7 million.
Quanterix also continued expanding its diagnostics strategy. The company highlighted Anthem coverage for its Alzheimer’s disease test, ongoing market-access work, the launch of an ultra-sensitive NPTX2 immunoassay targeting an emerging biomarker of synaptic function, and two new spatial products.
Its LucentAD diagnostics platform is becoming an increasingly important part of that strategy. The company has received $897 pricing from CMS for LucentAD, secured an Anthem coverage policy and submitted its multi-marker test to the FDA. An IVD submission for the HD-X instrument is planned for 2027.
Quanterix’s Q2 GAAP results also included approximately $28.5 million of impairment and employee separation costs, including impairment charges associated with goodwill and an intangible asset related to the termination of a diagnostics development agreement assumed through the Akoya acquisition.
